Context

Cannabis Strains

Content

strain name: Given name of strain

type of strain: indica, sativa, hybrid

rating: user ratings averaged

effects: different effects optained

taste: taste of smoke

description: backround, etc

Acknowledgements

leafly.com

Inspiration

Marijuana may get a bad rep in the media as far as the decriminalization debate goes, but its health benefits can no longer go unnoticed. With various studies linking long-term marijuana use to positive, health-related effects, there are more than just a few reasons to smoke some weed every day.

A study done by the Boston Medical Center and the Boston University of Medicine, examined 589 drug users—more than 8 out of 10 of whom were pot smokers. It determined that “weed aficionados” were no more likely to visit the doctor than non-drug users. If an increased risk of contracting ailments is what’s preventing you from smoking more weed, it looks like you’re in the clear!

One of the greatest medicinal benefits of marijuana is its pain relieving qualities, which make it especially effective for treating chronic pain. From menstruation cramps to nerve pain, as little as three puffs of bud a day can help provide the same relief as synthetic painkillers. Marijuana relieves pain by “changing the way the nerves function,” says Mark Ware, MD and assistant professor of anesthesia and family medicine at McGill University.

Studies have found that patients suffering from arthritis could benefit from marijuana use. This is because naturally occurring chemicals in cannabis work to activate pathways in the body that help fight off joint inflammation.

Data for cities, communities, and City of Los Angeles Council Districts were generated using a small area estimation method which combined the survey data with population benchmark data (2022 population estimates for Los Angeles County) and neighborhood characteristics data (e.g., U.S. Census Bureau, 2017-2021 American Community Survey 5-Year Estimates). This indicator is based on self-report and includes adults who used any form of marijuana at least one time in the past month.Among federally prohibited drugs and substances, marijuana is the most commonly used. In early 2018, marijuana became legal for recreational sale and consumption in California. Using marijuana at any age can lead to negative health consequences, which include psychological conditions such as depression or anxiety; brain damage affecting memory, attention, and learning ability; lung and cardiovascular system damage; harm to developing fetuses or infants; and increased risk for motor vehicle crashes. Marijuana use has long been associated with the use of other substances, including alcohol, tobacco, and prescription and illicit narcotics. Cities and communities should take an active role in educating residents, particularly youth, pregnant persons, and other vulnerable groups, about the potential risks of marijuana use and adopt policies that regulate and ensure safe marijuana retail activity.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

The National Household Survey on Drug Abuse (NHSDA) series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions include age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including psychotherapeutics. Respondents were also asked about personal and family income sources and amounts, substance abuse treatment history, illegal activities, problems resulting from the use of drugs, need for treatment for drug or alcohol use, criminal record, and needle-sharing. Questions on mental health and access to care, which were introduced in the 1994-B questionnaire (see NATIONAL HOUSEHOLD SURVEY ON DRUG ABUSE, 1994), were retained in this administration of the survey. Also retained was the section on risk/availability of drugs that was reintroduced in 1996, and sections on driving behavior and personal behavior were added (see NATIONAL HOUSEHOLD SURVEY ON DRUG ABUSE, 1996). The 1997 questionnaire (NATIONAL HOUSEHOLD SURVEY ON DRUG ABUSE, 1997) introduced new items that the 1998 NHSDA continued on cigar smoking, people who were present when respondents used marijuana or cocaine for the first time (if applicable), reasons for using these two drugs the first time, reasons for using these two drugs in the past year, reasons for discontinuing use of these two drugs (for lifetime but not past-year users), and reasons respondents never used these two drugs. Both the 1997 and 1998 NHSDAs had a series of questions that were asked only of respondents aged 12 to 17. These items covered a variety of topics that may be associated with substance use and related behaviors, such as exposure to substance abuse prevention and education programs, gang involvement, relationship with parents, and substance use by friends. Demographic data include sex, race, age, ethnicity, marital status, educational level, job status, income level, veteran status, and current household composition. This study has 1 Data Set.

Medical cannabis legalization has sparked a surge in economic activity across the United States, with significant job creation, tax revenue generation, and potential cost savings. The establishment of marijuana nurseries and dispensaries has been a pivotal first step for states embracing medical cannabis, not only creating employment opportunities but also stimulating economic growth within the burgeoning cannabis industry.

Job Creation and Revenue Generation

Studies have revealed the substantial economic benefits of medical cannabis legalization. For instance, in Nevada, the legalization of recreational marijuana was projected to support over 41,000 jobs by 2024, generating more than $1.7 billion in labor income. Similarly, California could see at least 81,000 additional direct, indirect, and induced jobs, along with an increase in total labor income by at least $3.5 billion as a result of legalized marijuana sales. Moreover, nationwide legalization is anticipated to create 1 million jobs by 2025, spanning various sectors such as farming, processing, distribution, and sales of marijuana-based products.

Tax Revenue and Cost Savings

The taxation of medical cannabis has emerged as a significant source of revenue for states, with proceeds being channeled into programs that benefit local communities. For example, Colorado utilized a portion of its cannabis tax revenue, amounting to $7.3 million, for homeless services and housing. Furthermore, the potential federal tax revenue from legalizing cannabis, estimated at $131.8 billion between 2017 and 2025, could fund programs benefitting communities disproportionately affected by the war on drugs, as indicated by the Washington Post. Additionally, the American Civil Liberties Union estimates that repurposing a portion of the $7.7 billion spent annually on enforcing the war on drugs could redirect funding towards community programs and cannabis education and regulation. Future Outlook

The rapid growth of the medical cannabis industry is expected to continue, with projections indicating a 250% increase in legal cannabis jobs over the next decade, surpassing growth rates of other industries. The economic impact of federally legalizing cannabis could provide a substantial stimulus to the economy, potentially leading to nationwide decriminalization and the redirection of significant budgetary allocations from ineffective prohibition towards reparations for affected communities. As the industry evolves, the economic benefits of medical cannabis on job creation, tax revenue, and cost savings continue to reinforce its potential as a transformative force in the US economy.

Who Buys Medical Cannabis?

The demographic profile of individuals purchasing medical cannabis is quite diverse, reflecting a range of ages, genders, and socioeconomic backgrounds. Research indicates that medical cannabis users encompass a broad spectrum, with a notable representation of individuals seeking alternative treatment options for various health conditions. While the stereotype of the typical cannabis user may have been previously associated with a specific demographic, the reality is far more multifaceted, with individuals from different walks of life turning to medical cannabis to address their health needs.

Studies have shown that medical cannabis users consist of individuals across different age groups, from young adults to older individuals, as well as those from various ethnic backgrounds. These users often seek relief from a range of health issues, including chronic pain, anxiety, and other medical conditions, driving the demand for medical cannabis products. Additionally, there's a growing trend of older adults turning to medical cannabis as a potential alternative to traditional medications, fueling the expansion of the market and reshaping the demographic landscape of medical cannabis users.

The increasing availability of medical cannabis across various US jurisdictions has contributed to a broader and more inclusive consumer base, with individuals from diverse educational and income backgrounds accessing these products. As the acceptance and use of medical cannabis continue to evolve, it's clear that the consumer profile is not confined to a specific demographic, but rather reflects a wide array of individuals seeking alternative health solutions, thereby reshaping the landscape of the medical cannabis market.

Medical Cannabis Regulations in the USA

Medical cannabis regulations in the USA vary significantly among states, reflecting a patchwork of policies governing the use, distribution, and cultivation of cannabis products. As of April 2023, 38 states, three territories, and the District of Columbia have legalized the medical use of cannabis, each with its own set of statutory language and program specifics. These regulations encompass aspects such as patient r...

EMSIndicators:The number of individual patients administered naloxone by EMSThe number of naloxone administrations by EMSThe rate of EMS calls involving naloxone administrations per 10,000 residentsData Source:The Vermont Statewide Incident Reporting Network (SIREN) is a comprehensive electronic prehospital patient care data collection, analysis, and reporting system. EMS reporting serves several important functions, including legal documentation, quality improvement initiatives, billing, and evaluation of individual and agency performance measures.Law Enforcement Indicators:The Number of law enforcement responses to accidental opioid-related non-fatal overdosesData Source:The Drug Monitoring Initiative (DMI) was established by the Vermont Intelligence Center (VIC) in an effort to combat the opioid epidemic in Vermont. It serves as a repository of drug data for Vermont and manages overdose and seizure databases. Notes:Overdose data provided in this dashboard are derived from multiple sources and should be considered preliminary and therefore subject to change. Overdoses included are those that Vermont law enforcement responded to. Law enforcement personnel do not respond to every overdose, and therefore, the numbers in this report are not representative of all overdoses in the state. The overdoses included are limited to those that are suspected to have been caused, at least in part, by opioids. Inclusion is based on law enforcement's perception and representation in Records Management Systems (RMS). All Vermont law enforcement agencies are represented, with the exception of Norwich Police Department, Hartford Police Department, and Windsor Police Department, due to RMS access. Questions regarding this dataset can be directed to the Vermont Intelligence Center at dps.vicdrugs@vermont.gov.Overdoses Indicators:The number of accidental and undetermined opioid-related deathsThe number of accidental and undetermined opioid-related deaths with cocaine involvementThe percent of accidental and undetermined opioid-related deaths with cocaine involvementThe rate of accidental and undetermined opioid-related deathsThe rate of heroin nonfatal overdose per 10,000 ED visitsThe rate of opioid nonfatal overdose per 10,000 ED visitsThe rate of stimulant nonfatal overdose per 10,000 ED visitsData Source:Vermont requires towns to report all births, marriages, and deaths. These records, particularly birth and death records are used to study and monitor the health of a population. Deaths are reported via the Electronic Death Registration System. Vermont publishes annual Vital Statistics reports.The Electronic Surveillance System for the Early Notification of Community-based Epidemics (ESSENCE) captures and analyzes recent Emergency Department visit data for trends and signals of abnormal activity that may indicate the occurrence of significant public health events.Population Health Indicators:The percent of adolescents in grades 6-8 who used marijuana in the past 30 daysThe percent of adolescents in grades 9-12 who used marijuana in the past 30 daysThe percent of adolescents in grades 9-12 who drank any alcohol in the past 30 daysThe percent of adolescents in grades 9-12 who binge drank in the past 30 daysThe percent of adolescents in grades 9-12 who misused any prescription medications in the past 30 daysThe percent of adults who consumed alcohol in the past 30 daysThe percent of adults who binge drank in the past 30 daysThe percent of adults who used marijuana in the past 30 daysData Sources:The Vermont Youth Risk Behavior Survey (YRBS) is part of a national school-based surveillance system conducted by the Centers for Disease Control and Prevention (CDC). The YRBS monitors health risk behaviors that contribute to the leading causes of death and disability among youth and young adults.The Behavioral Risk Factor Surveillance System (BRFSS) is a telephone survey conducted annually among adults 18 and older. The Vermont BRFSS is completed by the Vermont Department of Health in collaboration with the Centers for Disease Control and Prevention (CDC).Notes:Prevalence estimates and trends for the 2021 Vermont YRBS were likely impacted by significant factors unique to 2021, including the COVID-19 pandemic and the delay of the survey administration period resulting in a younger population completing the survey. Students who participated in the 2021 YRBS may have had a different educational and social experience compared to previous participants. Disruptions, including remote learning, lack of social interactions, and extracurricular activities, are likely reflected in the survey results. As a result, no trend data is included in the 2021 report and caution should be used when interpreting and comparing the 2021 results to other years.The Vermont Department of Health (VDH) seeks to promote destigmatizing and equitable language. While the VDH uses the term "cannabis" to reflect updated terminology, the data sources referenced in this data brief use the term "marijuana" to refer to cannabis. Prescription Drugs Indicators:The average daily MMEThe average day's supplyThe average day's supply for opioid analgesic prescriptionsThe number of prescriptionsThe percent of the population receiving at least one prescriptionThe percent of prescriptionsThe proportion of opioid analgesic prescriptionsThe rate of prescriptions per 100 residentsData Source:The Vermont Prescription Monitoring System (VPMS) is an electronic data system that collects information on Schedule II-IV controlled substance prescriptions dispensed by pharmacies. VPMS proactively safeguards public health and safety while supporting the appropriate use of controlled substances. The program helps healthcare providers improve patient care. VPMS data is also a health statistics tool that is used to monitor statewide trends in the dispensing of prescriptions.Treatment Indicators:The number of times a new substance use disorder is diagnosed (Medicaid recipients index events)The number of times substance use disorder treatment is started within 14 days of diagnosis (Medicaid recipients initiation events)The number of times two or more treatment services are provided within 34 days of starting treatment (Medicaid recipients engagement events)The percent of times substance use disorder treatment is started within 14 days of diagnosis (Medicaid recipients initiation rate)The percent of times two or more treatment services are provided within 34 days of starting treatment (Medicaid recipients engagement rate)The MOUD treatment rate per 10,000 peopleThe number of people who received MOUD treatmentData Source:Vermont Medicaid ClaimsThe Vermont Prescription Monitoring System (VPMS)Substance Abuse Treatment Information System (SATIS)

OpenSprayer.com

Open Sprayer will hopefully be an open sourced autonomous land drone that will propel itself across the fields spraying weeds it can see with its mounted cameras. The project should involve a mix of mechanical engineering, classical software design and machine learning to achieve its goal. The project is meant to be a DIY effort to compete with the big companies like John Deere currently developing similar tech. The benefit of an open design is cheaper capital and maintenance cost. The ability to fix, update and repair your own sprayer would offer a great alternative to the potential high running costs of branded machines.

The data set includes pictures of broad leaved docks and picture of the land without broad leaved docks. I plan to update the images to better reflect the images that the sprayer drone will produce when operating. Give me feedback and I can take more pictures to improve the dataset.

Worked full-time, year-round in the past 12 months Poverty Rate Statistics for 2022. This is part of a larger dataset covering poverty in Weed, California by age, education, race, gender, work experience and more.